Mindera Health™ launches pilot project with the National Health Insurance Company to improve the management of… | News


San Diego, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform – the first achievement in precision medicine in psoriasis, has launched a pilot program in California and Texas with a health insurance company to evaluate the company’s revolutionary Mind.Px™ test. The pilot program will assess trends in physician utilization, patient outcomes, medication switching, and overall net savings compared to a control group.

Mind.Px™ uses a painless Dermal Biomarker Patch (DBP) to match each patient with moderate to severe psoriasis to the most effective therapy for that unique patient, creating immense savings for the healthcare system and improving outcomes for patients. Mind.Px™ DBP and AI technology predicts (91% PPV) the appropriate biologic drug class for an individual patient prior to treatment. By matching the patient to the correct drug class before treatment begins, payers can potentially save up to $15,000 per patient in avoidable drugs through “trial and error” and could save millions of dollars for small groups up to hundreds of millions of dollars for large groups. plans.

“Using a pilot project to validate our projected cost savings while improving patient outcomes is the first of many steps to accelerating Mind.Px’s national coverage,” said George Mahaffey, President and CEO of Mindera Health.

Spending on specialty drugs is growing at exponential rates, and biologics are often identified by payers, employers, and pharmacy benefit managers as a top drug spend each year.[i] Mind.Px addresses this issue directly with high medical utility (90%+) to optimize form performance.

Ann Deren-Lewis, Chief Commercial Officer, adds, “Mind.Px is intended to reduce the trial-and-error process of prescribing biologics and to help pharmacy benefit managers and insurers reduce overspending while improving patient outcomes. »

About Mind.Px™

Mind.Px is Mindera Health’s flagship assay designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample and data analysis, Mind.Px dramatically improves patient outcomes and significantly reduces healthcare system costs of biologic treatments expensive.

About Mindera Health™

Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of molecular-level skin analysis. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. To learn more, visit www.minderahealth.com.


[i] Source: Prime Therapeutics 2012-2015 and 2019-2020 posters titled “Prevalence and Cost of Autoimmune Specialty Drug Use by Indication”.

George Mahaffey Mindera Health (858) 810-6070 [email protected]

Copyright 2022 GlobeNewswire, Inc.


About Author

Comments are closed.